DOCSLIB.ORG

Search Strategy Systematic Review of Effect of Statins and Antiplatelets On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Search Strategy Systematic Review of Effect of Statins and Antiplatelets On Embase.com (Embase incl. Medline) ('D dimer'/de OR ('D-dimer' OR 'D-dimers' OR 'D1 dimer' OR 'fibrin fragment DD' OR (crosslinked NEAR/3 fibrin* NEAR/3 degradation)):ab,ti) AND ('hydroxymethylglutaryl coenzyme A reductase inhibitor'/exp OR 'antithrombocytic agent'/exp OR (((Hydroxymethylglutaryl OR HMG) NEAR/3 (CoA OR 'Coenzyme A') NEAR/3 (inhibitor*)) OR atorvastatin* OR bervastatin* OR cerivastatin* OR crilvastatin* OR dalvastatin* OR fluvastatin* OR fluindostatin* OR glenvastatin* OR lovastatin* OR mevinolin* OR mevastatin* OR compactin* OR pitavastatin* OR pravastatin* OR rosuvastatin* OR simvastatin* OR tenivastatin* OR Zocor* OR Lipitor* OR selektin* OR lescol* OR statin* OR ((platelet* OR thrombocyt*) NEAR/3 (inhibitor* OR antiaggregant* OR antagonist*)) OR (anti NEXT/1 (platelet* OR thrombocyt*)) OR antiplatelet* OR antithrombocyt* OR 'acetylsalylic acid' OR ((acetyl*) NEXT/1 (salicyl*)) OR aspirin* OR caprin* OR aspro* OR Easprin* OR ZORprin* OR aspegic* OR anagrelide* OR ataprost* OR atopaxar* OR beraprost* OR cangrelor* OR kengreal* OR kengrexal* OR cilostazol* OR clopidogrel* OR grepid* OR iscover* OR Plavix* OR dazoxiben* OR dehydrocilostazol* OR dipyridam* OR dipiridam* OR dipyrol* OR Persantin* OR elinogrel* OR abciximab OR eptifibatide* OR integrilin* OR integrelin* OR lefradafiban* OR lotrafiban* OR orbofiban* OR roxifiban* OR sibrafiban* OR tirofiban* OR Aggrastat* OR agrastat* OR xemilofiban* OR ifetroban* OR iloprost* OR ciloprost* OR Ventavist* OR indobufen* OR itazigrel* OR linotroban* OR nafazotrom* OR naxaprostene* OR octimibate* OR oxagrelate* OR pamicogrel* OR pentoxifylline* OR oxpentifylline* OR Trental* OR picotamide* OR plafibride* OR prasugrel* OR Effient* OR Efient* OR epoprostenol* OR cycloprostin* OR Flolan* OR prostavasin* OR Alpostadil* OR regrelor* OR samixogrel* OR sarpogrelate* OR satigrel* OR sulfinpyrazon* OR sulphinpyrazon* OR Anturan* OR taprostene* OR temanogrel* OR terbogrel* OR terutroban* OR ticagrelor* OR brilique* OR possia* OR ticlopidine* OR Ticlid* OR triflusal* OR disgren* OR thrombodipin* OR (thrombin* NEAR/3 (antagonist* OR block*)) OR vorapaxar* OR zontivity*):ab,ti) NOT ('Conference Abstract'/it OR 'case report'/de) Medline Epub (Ovid) (("fibrin fragment D" OR "D-dimer" OR "D-dimers" OR D1-dimer*).mp. OR ("D-dimer" OR "D-dimers" OR "D1 dimer" OR "fibrin fragment DD" OR (crosslinked ADJ3 fibrin* ADJ3 degradation)).ab,ti.) AND ("Hydroxymethylglutaryl-CoA Reductase Inhibitors".mp. OR "Platelet Aggregation Inhibitors"/ OR (((Hydroxymethylglutaryl OR HMG) ADJ3 (CoA OR "Coenzyme A") ADJ3 (inhibitor*)) OR atorvastatin* OR bervastatin* OR cerivastatin* OR crilvastatin* OR dalvastatin* OR fluvastatin* OR fluindostatin* OR glenvastatin* OR lovastatin* OR mevinolin* OR mevastatin* OR compactin* OR pitavastatin* OR pravastatin* OR rosuvastatin* OR simvastatin* OR tenivastatin* OR Zocor* OR Lipitor* OR selektin* OR lescol* OR statin* OR ((platelet* OR thrombocyt*) ADJ3 (inhibitor* OR antiaggregant* OR antagonist*)) OR (anti ADJ (platelet* OR thrombocyt*)) OR antiplatelet* OR antithrombocyt* OR "acetylsalylic acid" OR ((acetyl*) ADJ (salicyl*)) OR aspirin* OR caprin* OR aspro* OR Easprin* OR ZORprin* OR aspegic* OR anagrelide* OR ataprost* OR atopaxar* OR beraprost* OR cangrelor* OR kengreal* OR kengrexal* OR cilostazol* OR clopidogrel* OR grepid* OR iscover* OR Plavix* OR dazoxiben* OR dehydrocilostazol* OR dipyridam* OR dipiridam* OR dipyrol* OR Persantin* OR elinogrel* OR abciximab OR eptifibatide* OR integrilin* OR integrelin* OR lefradafiban* OR lotrafiban* OR orbofiban* OR roxifiban* OR sibrafiban* OR tirofiban* OR Aggrastat* OR agrastat* OR xemilofiban* OR ifetroban* OR iloprost* OR ciloprost* OR Ventavist* OR indobufen* OR itazigrel* OR linotroban* OR nafazotrom* OR naxaprostene* OR octimibate* OR oxagrelate* OR pamicogrel* OR pentoxifylline* OR oxpentifylline* OR Trental* OR picotamide* OR plafibride* OR prasugrel* OR Effient* OR Efient* OR epoprostenol* OR cycloprostin* OR Flolan* OR prostavasin* OR Alpostadil* OR regrelor* OR samixogrel* OR sarpogrelate* OR satigrel* OR sulfinpyrazon* OR sulphinpyrazon* OR Anturan* OR taprostene* OR temanogrel* OR terbogrel* OR terutroban* OR ticagrelor* OR brilique* OR possia* OR ticlopidine* OR Ticlid* OR triflusal* OR disgren* OR thrombodipin* OR (thrombin* ADJ3 (antagonist* OR block*)) OR vorapaxar* OR zontivity*).ab,ti.) Cochrane Central (('D-dimer' OR 'D-dimers' OR 'D1 dimer' OR 'fibrin fragment DD' OR (crosslinked NEAR/3 fibrin* NEAR/3 degradation)):ab,ti) AND ((((Hydroxymethylglutaryl OR HMG) NEAR/3 (CoA OR 'Coenzyme A') NEAR/3 (inhibitor*)) OR atorvastatin* OR bervastatin* OR cerivastatin* OR crilvastatin* OR dalvastatin* OR fluvastatin* OR fluindostatin* OR glenvastatin* OR lovastatin* OR mevinolin* OR mevastatin* OR compactin* OR pitavastatin* OR pravastatin* OR rosuvastatin* OR simvastatin* OR tenivastatin* OR Zocor* OR Lipitor* OR selektin* OR lescol* OR statin* OR ((platelet* OR thrombocyt*) NEAR/3 (inhibitor* OR antiaggregant* OR antagonist*)) OR (anti NEXT/1 (platelet* OR thrombocyt*)) OR antiplatelet* OR antithrombocyt* OR 'acetylsalylic acid' OR ((acetyl*) NEXT/1 (salicyl*)) OR aspirin* OR caprin* OR aspro* OR Easprin* OR ZORprin* OR aspegic* OR anagrelide* OR ataprost* OR atopaxar* OR beraprost* OR cangrelor* OR kengreal* OR kengrexal* OR cilostazol* OR clopidogrel* OR grepid* OR iscover* OR Plavix* OR dazoxiben* OR dehydrocilostazol* OR dipyridam* OR dipiridam* OR dipyrol* OR Persantin* OR elinogrel* OR abciximab OR eptifibatide* OR integrilin* OR integrelin* OR lefradafiban* OR lotrafiban* OR orbofiban* OR roxifiban* OR sibrafiban* OR tirofiban* OR Aggrastat* OR agrastat* OR xemilofiban* OR ifetroban* OR iloprost* OR ciloprost* OR Ventavist* OR indobufen* OR itazigrel* OR linotroban* OR nafazotrom* OR naxaprostene* OR octimibate* OR oxagrelate* OR pamicogrel* OR pentoxifylline* OR oxpentifylline* OR Trental* OR picotamide* OR plafibride* OR prasugrel* OR Effient* OR Efient* OR epoprostenol* OR cycloprostin* OR Flolan* OR prostavasin* OR Alpostadil* OR regrelor* OR samixogrel* OR sarpogrelate* OR satigrel* OR sulfinpyrazon* OR sulphinpyrazon* OR Anturan* OR taprostene* OR temanogrel* OR terbogrel* OR terutroban* OR ticagrelor* OR brilique* OR possia* OR ticlopidine* OR Ticlid* OR triflusal* OR disgren* OR thrombodipin* OR (thrombin* NEAR/3 (antagonist* OR block*)) OR vorapaxar* OR zontivity*):ab,ti) Web of Science TS=((("D-dimer" OR (fibrin NEAR/1 fragment NEAR/1 DD) OR (crosslinked NEAR/2 fibrin* NEAR/2 degradation))) AND ((((Hydroxymethylglutaryl OR HMG) NEAR/4 (inhibitor*)) OR atorvastatin* OR bervastatin* OR cerivastatin* OR crilvastatin* OR dalvastatin* OR fluvastatin* OR fluindostatin* OR glenvastatin* OR lovastatin* OR mevinolin* OR mevastatin* OR compactin* OR pitavastatin* OR pravastatin* OR rosuvastatin* OR simvastatin* OR tenivastatin* OR Zocor* OR Lipitor* OR selektin* OR lescol* OR statin* OR ((platelet* OR thrombocyt*) NEAR/2 (inhibitor* OR antiaggregant* OR antagonist*)) OR (anti NEAR/1 (platelet* OR thrombocyt*)) OR antiplatelet* OR antithrombocyt* OR "acetylsalylic acid" OR ((acetyl*) NEAR/1 (salicyl*)) OR aspirin* OR caprin* OR aspro* OR Easprin* OR ZORprin* OR aspegic* OR anagrelide* OR ataprost* OR atopaxar* OR beraprost* OR cangrelor* OR kengreal* OR kengrexal* OR cilostazol* OR clopidogrel* OR grepid* OR iscover* OR Plavix* OR dazoxiben* OR dehydrocilostazol* OR dipyridam* OR dipiridam* OR dipyrol* OR Persantin* OR elinogrel* OR abciximab OR eptifibatide* OR integrilin* OR integrelin* OR lefradafiban* OR lotrafiban* OR orbofiban* OR roxifiban* OR sibrafiban* OR tirofiban* OR Aggrastat* OR agrastat* OR xemilofiban* OR ifetroban* OR iloprost* OR ciloprost* OR Ventavist* OR indobufen* OR itazigrel* OR linotroban* OR nafazotrom* OR naxaprostene* OR octimibate* OR oxagrelate* OR pamicogrel* OR pentoxifylline* OR oxpentifylline* OR Trental* OR picotamide* OR plafibride* OR prasugrel* OR Effient* OR Efient* OR epoprostenol* OR cycloprostin* OR Flolan* OR prostavasin* OR Alpostadil* OR regrelor* OR samixogrel* OR sarpogrelate* OR satigrel* OR sulfinpyrazon* OR sulphinpyrazon* OR Anturan* OR taprostene* OR temanogrel* OR terbogrel* OR terutroban* OR ticagrelor* OR brilique* OR possia* OR ticlopidine* OR Ticlid* OR triflusal* OR disgren* OR thrombodipin* OR (thrombin* NEAR/2 (antagonist* OR block*)) OR vorapaxar* OR zontivity*))) AND DT=(Article OR Review) Google Scholar: 100 (top relevance) "D-dimer"|"D-dimers"|"D1 dimer" statin|statins|"hydroxymethylglutaryl|HMG CoA reductase"|antiplatelet|antiplatelets|"platelet aggregation inhibitors"|"platelet antagonist" .
Load more

Recommended publications
  • VTE) Cindy Ward, DNP, RN-BC, CMSRN, ACNS-BC
    Chronic Complications of Venous Thromboembolism (VTE) Cindy Ward, DNP, RN-BC, CMSRN, ACNS-BC Roanoke, VA Disclosure • The speaker has no conflicts of interest to disclose. Carilion Roanoke Memorial Hospital • 3 time Magnet® designated • Flagship of Carilion Clinic, a 7 hospital system • Region’s only Level 1 Trauma Center • 703-bed academic medical center • System-wide, serves nearly 1 million patients across Virginia, West Virginia and North Carolina Objectives At the conclusion of this education activity, the learner will be able to: • recall VTE risk factors and prevention • describe post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension (CTEPH) • identify nursing implications of caring for patients with post-thrombotic syndrome and CTEPH What is VTE? Pulmonary Embolus Deep Vein (PE) Thrombosis (DVT) Signs/Symptoms of DVT • Swelling • Erythema • Pain • Warmth1 Signs/Symptoms of PE 1 • Sudden onset of dyspnea • Tachycardia • Irregular heartbeat • Chest pain, worse with deep breath • Hemoptysis • Low blood pressure, light-headedness or syncope • 350,000 – 900,000 people per year are affected by VTE1, 2 • VTE is the leading cause of preventable hospital death in the US2 • VTE can occur without symptoms (silent)3 Quick Facts • Patients with DVT who are untreated have a 37% incidence of PE that is fatal4 • Combined mortality from PE (initial and recurrence) is 73%4 Quick Facts • 1 in 20 hospitalized patients will suffer a fatal PE if they have not received adequate VTE prophylaxis5 • For 25% of patients with PE, the first
    [Show full text]
  • NTP42, a Novel Antagonist of the Thromboxane Receptor, Attenuates Experimentally Induced Pulmonary Arterial Hypertension Eamon P
    Mulvaney et al. BMC Pulmonary Medicine (2020) 20:85 https://doi.org/10.1186/s12890-020-1113-2 RESEARCH ARTICLE Open Access NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension Eamon P. Mulvaney1, Helen M. Reid1,2, Lucia Bialesova1, Annie Bouchard3, Dany Salvail3 and B. Therese Kinsella1,2* Abstract Background: NTP42 is a novel antagonist of the thromboxane prostanoid receptor (TP), currently in development for the treatment of pulmonary arterial hypertension (PAH). PAH is a devastating disease with multiple pathophysiological hallmarks including excessive pulmonary vasoconstriction, vascular remodelling, inflammation, fibrosis, in situ thrombosis and right ventricular hypertrophy. Signalling through the TP, thromboxane (TX) A2 is a potent vasoconstrictor and mediator of platelet aggregation. It is also a pro-mitogenic, pro-inflammatory and pro-fibrotic agent. Moreover, the TP also mediates the adverse actions of the isoprostane 8-iso-prostaglandin F2α, a free-radical-derived product of arachidonic acid produced in abundance during oxidative injury. Mechanistically, TP antagonists should treat most of the hallmarks of PAH, including inhibiting the excessive vasoconstriction and pulmonary artery remodelling, in situ thrombosis, inflammation and fibrosis. This study aimed to investigate the efficacy of NTP42 in the monocrotaline (MCT)-induced PAH rat model, alongside current standard-of-care drugs. Methods: PAH was induced by subcutaneous injection of 60 mg/kg MCT in male Wistar–Kyoto rats. Animals were assigned into groups: 1. ‘No MCT’;2.‘MCT Only’;3.MCT+NTP42 (0.25mg/kgBID);4.MCT+Sildenafil(50mg/kgBID),and5.MCT+ Selexipag (1 mg/kg BID), where 28-day drug treatment was initiated within 24 h post-MCT.
    [Show full text]
  • Lawout Journal.Qxd
    University Heart Journal Vol. 6, No. 1, January 2010 Therapeutic Options for the Treatment of Pulmonary Hypertension Rownak Jahan Tamanna 1 1Department of Cardiology, BIRDEM Address for Correspondance Dr. Rownak Jahan Tamanna, Department of Cardiology, BIRDEM , Dhaka e- mail : [email protected] Abstract The therapy of pulmonary hypertension depends on the identification of underlying contributing factors. pulmonary arterial hypertension ( PAH) , which can be idiopathic or related to connective tissue disease, portal hypertension, HIV disease, inges - tion of certain drugs or toxins, or congenital heart disease, had no specific therapy until recently. However, the past decade has seen remarkable progress, and these heretofore devastating and usually lethal forms of pulmonary hypertension now often respond to one form of therapy or another, leading to improved functional capacity and even survival. The following will consider the major pharmacotherapy’s now available for PAH and suggest a framework for therapeutic decision-making. Key word : Pulmonary hypertension Introduction although they can be quite useful for ameliorating symp - Pulmonary hypertension refers to an abnormal elevation of toms, they do not significantly affect the natural history of pulmonary artery ( PA ) pressure (mean PA pressure > 25 mm the disease. Hg at rest and 30 mm Hg with exercise). Newer and more effective pharmacotherapy’s for PAH are It is a rare disease of unknown etiology, whereas secondary now available, starting with prostacyclins in 1996 and, more pulmonary hypertension is a complication of pulmonary, recently, endothelin receptor antagonists and phosphodi - cardiac and extrathoracic conditions. Unrelieved pulmonary esterase 5 inhibitors. Relative merits of the different thera - hypertension can lead to right heart failure.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Prevention of Atherothrombotic Events in Patients with Diabetes Mellitus: from Antithrombotic Therapies to New-Generation Glucose-Lowering Drugs
    CONSENSUS STATEMENT EXPERT CONSENSUS DOCUMENT Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs Giuseppe Patti1*, Ilaria Cavallari2, Felicita Andreotti3, Paolo Calabrò4, Plinio Cirillo5, Gentian Denas6, Mattia Galli3, Enrica Golia4, Ernesto Maddaloni 7, Rossella Marcucci8, Vito Maurizio Parato9,10, Vittorio Pengo6, Domenico Prisco8, Elisabetta Ricottini2, Giulia Renda11, Francesca Santilli12, Paola Simeone12 and Raffaele De Caterina11,13*, on behalf of the Working Group on Thrombosis of the Italian Society of Cardiology Abstract | Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse outcomes after a cardiovascular event has occurred. This situation might be caused, at least in part, by the prothrombotic status observed in patients with diabetes. Therefore, contemporary antithrombotic strategies, including more potent agents or drug combinations, might provide greater clinical benefit in patients with diabetes than in those without diabetes. In this Consensus Statement, our Working Group explores the mechanisms of platelet and coagulation activity , the current debate on antiplatelet therapy in primary cardiovascular disease prevention, and the benefit of various antithrombotic approaches in secondary prevention of cardiovascular disease in patients with diabetes. While acknowledging that current data are often derived from underpowered, observational studies or subgroup analyses of larger trials, we propose
    [Show full text]
  • Stroke Prevention in Chronic Kidney Disease Disclosures
    5/18/2020 Controversies: Stroke Prevention in Chronic Kidney Disease Wei Ling Lau, MD FASN FAHA FACP Assistant Professor, Nephrology University of California, Irvine Visiting Fellow at OptumLabsCOPY Disclosures • Prior or current research funding from NIH, AHA, Sanofi, ZS Pharma, and Hub Therapeutics. • Associate Medical Director for home peritoneal dialysis at Fresenius University Dialysis Center of Orange. • Has beenNOT on Fresenius medical advisory board for Velphoro. • No conflicts of interest relevant to the current talk. Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 1 5/18/2020 Stroke Prevention in CKD • Blood pressure targets • Antiplatelet agents • Statins • Anticoagulation Controversies: Stroke prevention in CKD Wei Ling Lau, MD COPY BP TARGETS Data is limited, as patients with CKD were historically excluded from clinical trials NOT Whelton 2017 ACC/AHA hypertension guidelines [Hypertension 2018] Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 2 5/18/2020 Systolic Blood Pressure Intervention Trial SPRINT: BP lowering to <120 vs <140 mmHg significantly lowered rate of CVD composite primary outcome; no clear effect on stroke Controversies: Stroke prevention in CKD The SPRINT Research Group. N Engl J Med 2015 p2103 Wei Ling Lau, MD COPY SPRINT subgroup analysis: CKD • Patients with CKD stage 3‐4 (eGFR of 20 to <60) comprised 28% of the SPRINT study population • Intensive BP management seemed to provide the same benefits for reduction in the CVD composite primary outcomeNOT – but did not impact stroke Controversies: Stroke prevention in CKD Cheung 2017 J Am Soc Nephrol p2812 Wei Ling Lau, MD DO 3 5/18/2020 The hazard of incident stroke associated with systolic BP (SBP) and chronic kidney disease (CKD)BP using and an unadjusted stroke model risk: that contained J‐shaped dummy variables association for CKD and BP groups (A) and a fully adjusted model that contained dummy variables for CKD and BP grou..
    [Show full text]
  • Toward an in Vitro Bioequivalence Test
    TOWARD AN IN VITRO BIOEQUIVALENCE TEST by Jie Sheng A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmaceutical Sciences) In The University of Michigan 2007 Doctoral Committee: Professor Gordon L. Amidon, Chair Professor Henry Y. Wang Associate Professor Nair Rodriguez-Hornedo Associate Professor Steven P. Schwendeman Jie Sheng © 2007 All Rights Reserved To Kurt Q. Zhu, my husband and my very best friend, and to Diana S. Zhu and Brandon D. Zhu, my lovely children. ii Acknowledgements Most of all, I thank Prof. Gordon L. Amidon, for his support, guidance, and inspiration during my graduate studies at the University of Michigan. Being his student is the best step happened in my career. I am always amazed by his vision, energy, patience and dedication to the research and his students. He trained me to grow as a scientist and as a person. I also wish to thank all of my committee members, Professors David Fleisher, Nair Rodriguez-Hornedo, Steven Schwendeman and Henry Wang, for their very insightful and constructive suggestions to my research. It took all their efforts to raise me as a professional scientist in pharmaceutical field. They all contributed significantly to development and improvement of my graduate work. Especially, Prof. Wang has also guided me in thinking of career development as if 20-year later. I felt to be his student in many ways. I thank mentors, colleagues and friends, Prof. John Yu from Ohio State University, Paul Sirois from Eli Lilly, Kurt Seefeldt, Chet Provoda, Jonathan Miller, John Chung, Chris Landoswki, Haili Ping and Yasuhiro Tsume from College of Pharmacy, for many interesting discussions throughout the graduate program.
    [Show full text]
  • CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions
    Review CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions Rossana Roncato 1,*,†, Jacopo Angelini 2,†, Arianna Pani 2,3,†, Erika Cecchin 1, Andrea Sartore-Bianchi 2,4, Salvatore Siena 2,4, Elena De Mattia 1, Francesco Scaglione 2,3,‡ and Giuseppe Toffoli 1,‡ 1 1 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081 Aviano, Italy; [email protected] (E.C.); [email protected] (E.D.M.); [email protected] (G.T.) 2 Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy; [email protected] (J.A.); [email protected] (A.P.); [email protected] (A.S-B.); [email protected] (S.S.); [email protected] (F.S.) 3 Clinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore 3, 20162 Milan, Italy 4 Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy * Correspondence: [email protected]; Tel.:+390434659130 † These authors contributed equally. ‡ These authors share senior authorship. Int. J. Mol. Sci. 2020, 21, x; doi: www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2020, 21, x 2 of 8 Table S1. Co-administered agents categorized according to their potential risk for Drug-Drug interaction (DDI) in combination with CDK4/6 inhibitors (CDKis). Colors suggest the risk of DDI with CDKis: green, low risk DDI; orange, moderate risk DDI; red, high risk DDI. ADME, absorption, distribution, metabolism, and excretion; GI, Gastrointestinal; TdP, Torsades de Pointes; NTI, narrow therapeutic index. * Cardiological toxicity should be considered especially for ribociclib due to the QT prolongation.
    [Show full text]
  • GTH 2021 State of the Art—Cardiac Surgery: the Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery
    Review Article 59 GTH 2021 State of the Art—Cardiac Surgery: The Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery Laura Ranta1 Emmanuelle Scala1 1 Department of Anesthesiology, Cardiothoracic and Vascular Address for correspondence Emmanuelle Scala, MD, Centre Anesthesia, Lausanne University Hospital (CHUV), Lausanne, Hospitalier Universitaire Vaudois, Rue du Bugnon 46, BH 05/300, 1011 Switzerland Lausanne, Suisse, Switzerland (e-mail: [email protected]). Hämostaseologie 2021;41:59–62. Abstract Heparin-induced thrombocytopenia (HIT) is a severe, immune-mediated, adverse drug Keywords reaction that paradoxically induces a prothrombotic state. Particularly in the setting of ► Heparin-induced cardiac surgery, where full anticoagulation is required during cardiopulmonary bypass, thrombocytopenia the management of HIT can be highly challenging, and requires a multidisciplinary ► cardiac surgery approach. In this short review, the different perioperative strategies to run cardiopul- ► state of the art monary bypass will be summarized. Introduction genicity of the antibodies and is diagnostic for HIT. The administration of heparin to a patient with circulating Heparin-induced thrombocytopenia (HIT) is a severe, im- pathogenic HITabs puts the patient at immediate risk of mune-mediated, adverse drug reaction that paradoxically severe thrombotic complications. induces a prothrombotic state.1,2 Particularly in the setting The time course of HIT can be divided into four distinct of cardiac surgery, where full anticoagulation is required phases.6 Acute HIT is characterized by thrombocytopenia during cardiopulmonary bypass (CPB), the management of and/or thrombosis, the presence of HITabs, and confirma- HIT can be highly challenging, and requires a multidisciplin- tion of their platelet activating capacity by a functional ary approach.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • In Vitro and in Vivo Pharmacological Characterization of BM-613, a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane
    JPET Fast Forward. Published on December 30, 2004 as DOI: 10.1124/jpet.104.079301 JPET FastThis Forward. article has not Published been copyedited on andDecember formatted. The 30, final 2004 version as mayDOI:10.1124/jpet.104.079301 differ from this version. JPET #79301 In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist Julien Hanson*, Stephanie Rolin*, Denis Reynaud, Na Qiao, Leanne P. Kelley, Helen M. Reid, François Valentin, John Tippins, Therese B. Kinsella, Bernard Masereel, Cecil Pace- Downloaded from Asciak, Bernard Pirotte, and Jean-Michel Dogné Natural and Synthetic Drugs Research Centre, Department of Pharmacy, Laboratory of jpet.aspetjournals.org Medicinal Chemistry, University of Liège, 1, Av. de l'Hôpital, B-4000 Liège, Belgium. (J.H., J-M.D., B.P.) Department of Pharmacy, University of Namur, 61, rue de Bruxelles, B-5000 Namur, at ASPET Journals on September 24, 2021 Belgium. (S.R., B.M.) Programme in Integrative Biology, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. (D.R., N.Q., C.P-A.) Department of Biochemistry, Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Ireland. (L.P.K., H.M.R., T.B.K.) Department of Biological Sciences, Imperial College, Exhibition Road, London SW7 2AZ, United Kingdom. (F.V., J.T.) 1 Copyright 2004 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on December 30, 2004 as DOI: 10.1124/jpet.104.079301 This article has not been copyedited and formatted.
    [Show full text]
  • Role of Proaggregatory and Antiaggregatory Prostaglandins in Hemostasis
    Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. P Gresele, … , G Pieters, J Vermylen J Clin Invest. 1987;80(5):1435-1445. https://doi.org/10.1172/JCI113223. Research Article Thromboxane synthase inhibition can lead to two opposing effects: accumulation of proaggregatory cyclic endoperoxides and increased formation of antiaggregatory PGI2 and PGD2. The elimination of the effects of the cyclic endoperoxides by an endoperoxide-thromboxane A2 receptor antagonist should enhance the inhibition of hemostasis by thromboxane synthase blockers. We have carried out a series of double-blind, placebo-controlled, crossover studies in healthy volunteers to check if this hypothesis may be operative in vivo in man. In a first study, in 10 healthy male volunteers, the combined administration of the thromboxane receptor antagonist BM 13.177 and the thromboxane synthase inhibitor dazoxiben gave stronger inhibition of platelet aggregation and prolonged the bleeding time more than either drug alone. In a second study, in 10 different healthy male volunteers, complete inhibition of cyclooxygenase with indomethacin reduced the prolongation of the bleeding time by the combination BM 13.177 plus dazoxiben. In a third study, in five volunteers, selective cumulative inhibition of platelet TXA2 synthesis by low-dose aspirin inhibited platelet aggregation and prolonged the bleeding time less than the combination BM 13.177 plus dazoxiben. In vitro, in
    [Show full text]